Skip to main content

Table 5 Association between exposure to different oral osteoarthritis therapies and occurrence of knee replacement

From: Impact of oral osteoarthritis therapy usage among other risk factors on knee replacement: a nested case-control study using the Osteoarthritis Initiative cohort

 

Acetaminophen

NSAIDs

COX-2 inhibitors

Narcotics

Glucosamine/chondroitin sulfate

n

ORb

95% CI

p c

n

ORb

95% CI

p c

n

ORb

95% CI

p c

n

ORb

95% CI

p c

n

ORb

95% CI

p c

Primary analysis

 In the 3 years prior to index date (n = 521: 161 KR/360 controls)

  Exposure 1–79%a

124

1.09

(0.66–1.78)

0.745

313

1.05

(0.64–1.72)

0.839

68

1.13

(0.48–2.67)

0.784

67

1.00

(0.48–2.09)

0.995

120

0.85

(0.50–1.48)

0.573

  Exposure ≥ 80%a

14

1.11

(0.30–4.09)

0.872

44

1.66

(0.93–2.95)

0.086

21

1.15

(0.47–2.83)

0.761

  

ND

 

163

0.73

(0.43–1.23)

0.236

Secondary Analyses

 In the 2 years prior to index date (n = 642: 193 KR/449 controls)

  Exposure 1–79%a

210

1.10

(0.66–1.84)

0.722

369

0.96

(0.60–1.54)

0.853

88

1.40

(0.57–3.48)

0.465

77

1.19

(0.54–2.58)

0.670

255

0.70

(0.39–1.26)

0.235

  Exposure ≥ 80%a

20

1.46

(0.69–3.11)

0.322

58

1.41

(0.88–2.26)

0.159

27

1.18

(0.55–2.52)

0.671

  

ND

 

166

1.00

(0.65–1.55)

0.989

 In the 4 years prior to index date (n = 363: 121 KR/242 controls)

  Exposure 1–79%a

113

1.34

(0.74–2.41)

0.333

234

1.40

(0.78–2.52)

0.256

50

1.63

(0.64–4.13)

0.303

50

1.43

(0.62–3.33)

0.405

156

0.65

(0.33–1.25)

0.191

  Exposure ≥ 80%a

  

ND

 

26

1.65

(0.75–3.66)

0.215

  

ND

   

ND

 

83

0.63

(0.32–1.21)

0.165

 In the 5 years prior to index date (n = 228: 82 KR/146 controls)

  Exposure 1–79%a

60

1.38

(0.66–2.88)

0.397

110

1.88

(0.85–4.20)

0.121

18

1.35

(0.41–4.49)

0.623

33

1.19

(0.48–2.93)

0.706

54

0.90

(0.37–2.14)

0.803

  Exposure ≥ 80%a

15

1.66

(0.44–6.35)

0.457

45

2.27

(0.90–5.71)

0.081

  

ND

   

ND

 

70

0.73

(0.33–1.64)

0.445

  1. CI confidence interval, COX-2 cyclooxygenase-2, KR knee replacement, ND not determinable, n value too small, NSAIDs non-steroidal anti-inflammatory drugs, OA osteoarthritis, OR odds ratio
  2. aCompared to the “no exposure” category
  3. bAdjusted for race, body mass index, other medication for pain, joint space width, Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) stiffness, meniscal extrusion, bone marrow lesions, and Knee injury and Osteoarthritis Outcome Score (KOOS)
  4. cConditional logistic regression